Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has only been a few months since my previous Altimmune (NASDAQ: ALT ) article, where I pointed out the potential of Altimmune’s flagship candidate, pemvidutide “pemvi”, to be a major player in the obesity market, as well as carve out a subset ofHe is ...